Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6619965 | 0.87 | TSHR (0.56) | TSHRHPGDALDH1A1GAANOTUM | |
| SCHEMBL14846086 | 0.84 | CYP1A2 (0.58) | TSHRHPGDALDH1A1GAAKMT2A | |
| SCHEMBL14736015 | 0.84 | PDE10A (0.52) | TSHRHPGDALDH1A1GAAKMT2A | |
| SCHEMBL29096990 | 0.76 | ALDH1A1 (0.50) | TSHRHPGDALDH1A1GAAKMT2A | |
| SCHEMBL7001602 | 0.76 | ALDH1A1 (0.49) | TSHRHPGDALDH1A1GAAKMT2A | |
| SCHEMBL4516428 | 0.75 | GPR119 (0.53) | ALDH1A1KMT2AMEN1GPR119 | |
| SCHEMBL14679174 | 0.75 | MAPT (0.66) | TSHRHPGDALDH1A1KMT2A | |
| SCHEMBL3616245 | 0.75 | NOTUM (0.58) | TSHRALDH1A1GAAKMT2AMEN1 | |
| SCHEMBL4890499 | 0.74 | ALDH1A1 (0.45) | TSHRHPGDALDH1A1GAAKMT2A | |
| SCHEMBL14736589 | 0.74 | PDE10A (0.56) | TSHRHPGDALDH1A1GAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110086893-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | VERNALIS (OXFORD) LTD (GB) | 2011-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086893-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | MMP12, TIMP3, MMP9 | TSHR 1756/4885HPGD 37/4885ALDH1A1 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.